Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ISB 1442 |
Synonyms | |
Therapy Description |
ISB 1442 is a bispecific antibody that targets CD38 and CD47, potentially leading to enhanced tumor cell killing and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2903). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ISB 1442 | ISB-1442|ISB1442 | CD38 Antibody 20 CD47 Antibody 31 | ISB 1442 is a bispecific antibody that targets CD38 and CD47, potentially leading to enhanced tumor cell killing and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2903). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05427812 | Phase Ib/II | ISB 1442 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Recruiting | USA | AUS | 1 |